

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/613,262	07/03/2003	Eli Gilboa	1430/13	3315
JENKINS, WILSON, TAYLOR & HUNT, P. A. SUITE 1200, UNIVERSITY TOWER 3100 TOWER BOULEVARD DURHAM, NC 27707			EXAMINER	
			WEHBE, ANNE MARIE SABRINA	
			ART UNIT	PAPER NUMBER
Doldiam, No	27707		1633	
				•
			· MAIL DATE	DELIVERY MODE
			05/15/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

		Application No.	Applicant(s)			
Office Action Summary		10/613,262	GILBOA ET A	AL.		
		Examiner	Art Unit			
700		Anne Marie S. Weht	1	ta		
The MAILING DAT Period for Reply	E of this communication app	pears on the cover sh	eet with the correspondence	e address		
A SHORTENED STATUT WHICHEVER IS LONGE - Extensions of time may be availa after SIX (6) MONTHS from the r - If NO period for reply is specified - Failure to reply within the set or e	R, FROM THE MAILING DOWN THE PROPERTY DESCRIPTION OF THE P	ATE OF THIS COMI 36(a). In no event, however, will apply and will expire SIX . cause the application to be	MUNICATION. may a reply be timely filed 6) MONTHS from the mailing date of	this communication		
Status						
1) Responsive to com	munication(s) filed on <u>10 O</u>	ctober 2006				
2a) ☐ This action is FINA		action is non-final.				
	, _					
	ce with the practice under E					
Disposition of Claims		· ·				
_	e pending in the application.			-		
	aim(s) <u>1-9 and 16-18</u> is/are		sideration	•		
5) Claim(s) is/a	•					
6) Claim(s) is/a						
7) Claim(s) is/a	•					
	<u>1 19-35</u> are subject to restric	ction and/or election	requirement			
Application Papers						
	-1.5					
	objected to by the Examine					
	on is/are: a) acc			•		
	quest that any objection to the					
	sheet(s) including the correct					
11) I he oath or declara	tion is objected to by the Ex	caminer. Note the att	ached Office Action or forr	n PTO-152.		
Priority under 35 U.S.C. § 1	19					
	made of a claim for foreign	priority under 35 U.	S.C. § 119(a)-(d) or (f).			
	* c) None of:					
	ies of the priority document					
	ies of the priority document					
	e certified copies of the prior			onal Stage		
	om the International Bureau	` ' ' '				
* See the attached det	ailed Office action for a list	of the certified copie	s not received.			
			•			
Attachment(s)	TO 200)					
 Notice of References Cited (P Notice of Draftsperson's Pater 			rview Summary (PTO-413) er No(s)/Mail Date			
3) 🔲 Information Disclosure Statem	nent(s) (PTO/SB/08)	5) 🔲 Not	ce of Informal Patent Application	l		
Paper No(s)/Mail Date		6) 🗌 Oth	er:			

Page 2

Applicant's amendment and response received on 10/10/06 have been entered and forwarded to the examiner on 3/9/07. No claims have been canceled and new claims 19-35 have been added. Claims 1-35 are now pending in this application. Of these, claims 1-9 and 16-18 have been withdrawn, as being drawn to subject matter non-elected without traverse.

While new claims 19-35 are drawn to the elected invention of composition comprising an antigen presenting cell, the newly added claims contain new limitations regarding specific species of tumor antigens which have necessitated the following additional requirement for election of species. Please note that MPEP 808.01(a) states; "If applicant presents species claims to more than one patentably distinct species of the invention after an Office action on only generic claims, with no restriction requirement, the Office may require the applicant to elect a single species for examination". Claims 10-15 examined on the merits in the previous office action were drawn to the genus of tumor antigens and did not recite any specific species. New claims 21-22 and 28 now recite specific species of tumor antigens. As such the following requirement for election of species applies.

This application contains claims directed to the following patentably distinct species of tumor antigens:

- a) TERT
- b) TRP-2.

The species are independent or distinct because each tumor antigen is a distinct protein with materially different physical, chemical, and functional properties which is further encoded

Application/Control Number: 10/613,262

Art Unit: 1633

by unrelated mRNA sequences. Further, mRNA encoding each tumor antigen is expressed and/or derived from different types of tumor cells. As such, the search for each species is not coextensive and it would place an undue burden on the examiner in this stage of the prosecution to search and examine the species together.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, claims 10-15, 19-20, 23-27, and 29-35 are generic.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which depend from or otherwise require all the limitations of an allowable generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and

Art Unit: 1633

specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103(a) of the other invention.

Any inquiry concerning this communication from the examiner should be directed to Anne Marie S. Wehbé, Ph.D., whose telephone number is (571) 272-0737. If the examiner is not available, the examiner's supervisor, Joseph Woitach, can be reached at (571) 272-0739. For all official communications, **the new technology center fax number is (571) 273-8300**. Please note that all official communications and responses sent by fax must be directed to the technology center fax number. For informal, non-official communications only, the examiner's direct fax number is (571) 273-0737. For any inquiry of a general nature, please call (571) 272-0547.

The applicant can also consult the USPTO's Patent Application Information Retrieval system (PAIR) on the internet for patent application status and history information, and for electronic images of applications. For questions or problems related to PAIR, please call the USPTO Patent Electronic Business Center (Patent EBC) toll free at 1-866-217-9197. Representatives are available daily from 6am to midnight (EST). When calling please have your application serial number or patent number available. For all other customer support, please call the USPTO call center (UCC) at 1-800-786-9199.

Art Unit: 1633

Dr. A.M.S. Wehbé

ANNE M. WEHBE' PH.D PRIMARY EXAMINER

.

•

.